[Differential discovery strategies of bispecific and multi-specific antibody drugs].

Bispecific antibody drugs have enhanced efficacy and safety compared with therapeutic monoclonal antibody drugs, gradually becoming a new generation of effective therapies. With the development of genetic engineering and the maturity of the industry, increasing studies have been carried out on bispecific and multi-specific antibody drugs, and the application indications of these drugs are expanding, which lays a foundation for satisfying the clinical needs and creating clinical values. This paper provides a comprehensive review of the development stages, indications, target combinations, structural formats, and mechanisms of bispecific and multi-specific antibody drugs. It also discusses key points and strategies for differentiated drug discovery, facilitating the rapid development of innovative therapies, providing theoretical support for the clinical translation of these drugs, and offering more precise and effective treatment options for clinical practice.